Alaunos Therapeutics (TCRT) announced the appointment of Robert Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. Prior to joining his current company, Dr. Hofmeister spent almost seven years in scientific leadership at TCR2 Therapeutics (TCRR), a company developing novel therapies leveraging the TCR complex to fight both solid tumors and hematologic malignancies, culminating in the role of Chief Scientific Officer
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TCRT:
- Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
- Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
- Alaunos Therapeutics assumed with an Overweight at Wells Fargo
- Alaunos Therapeutics reports Q4 EPS (4c), consensus (7c)
- Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results